Search Results

PHT-427 200 mg  | Purity Not Available

TargetMol

PHT-427 (CS-0223) is a dual Akt (Ki: 2.7 μM) and PDPK1 (Ki: 5.2 μM) inhibitor (high-affinity binding for the PH domains of Akt and PDPK1).

More Information Supplier Page

CID755673 2 mg  | 99.74%

TargetMol

CID755673 is an effective and specific cell-active inhibitor for PKD (IC50: 182 nM); exhibits selective PKD1 inhibition when compared with PLK1, AKT, CAMKIIα, CAK, and PKC isoforms.

More Information Supplier Page

CID755673 100 mg  | 99.74%

TargetMol

CID755673 is an effective and specific cell-active inhibitor for PKD (IC50: 182 nM); exhibits selective PKD1 inhibition when compared with PLK1, AKT, CAMKIIα, CAK, and PKC isoforms.

More Information Supplier Page

Baricitinib 25 mg  | Purity Not Available

TargetMol

Baricitinib is an orally bioavailable inhibitor of Janus kinases 1 and 2 (JAK1/2), with potential anti-inflammatory, immunomodulating and antineoplastic activities.

More Information Supplier Page

Eltrombopag 200 mg  | Purity Not Available

TargetMol

Eltrombopag, an orally active thrombopoietin receptor agonist with megakaryopoiesis stimulating activity, binds to and stimulates the platelet thrombopoietin receptor (TPO-R or CD110).

More Information Supplier Page

Eltrombopag 100 mg  | Purity Not Available

TargetMol

Eltrombopag, an orally active thrombopoietin receptor agonist with megakaryopoiesis stimulating activity, binds to and stimulates the platelet thrombopoietin receptor (TPO-R or CD110).

More Information Supplier Page

Eltrombopag 25 mg  | Purity Not Available

TargetMol

Eltrombopag, an orally active thrombopoietin receptor agonist with megakaryopoiesis stimulating activity, binds to and stimulates the platelet thrombopoietin receptor (TPO-R or CD110).

More Information Supplier Page